Stanley-Laman Group’s Integra LifeSciences IART Stock Holding History

Stanley-Laman Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,000	Closed	-$230K	–	238
2023 Q1	$230K	Hold	4,000	–	–	0.04%	210
2022 Q4	$224K	Buy	+4,000	New	+$204K	0.04%	200
2022 Q3	–	Sell	-4,000	Closed	-$216K	–	257
2022 Q2	$216K	Hold	4,000	–	–	0.04%	259
2022 Q1	$257K	Hold	4,000	–	–	0.04%	256
2021 Q4	$268K	Hold	4,000	–	–	0.03%	246
2021 Q3	$274K	Hold	4,000	–	–	0.04%	241
2021 Q2	$273K	Hold	4,000	–	–	0.04%	234
2021 Q1	$276K	Hold	4,000	–	–	0.05%	226
2020 Q4	$260K	Buy	+4,000	New	+$215K	0.05%	223
2020 Q1	–	Sell	-4,000	Closed	-$233K	–	285
2019 Q4	$233K	Hold	4,000	–	–	0.06%	256
2019 Q3	$240K	Hold	4,000	–	–	0.06%	247
2019 Q2	$223K	Hold	4,000	–	–	0.05%	261
2019 Q1	$223K	Buy	+4,000	New	+$204K	0.05%	249
2018 Q4	–	Sell	-4,000	Closed	-$263K	–	273
2018 Q3	$263K	Hold	4,000	–	–	0.06%	199
2018 Q2	$258K	Hold	4,000	–	–	0.06%	241
2018 Q1	$221K	Buy	+4,000	New	+$210K	0.05%	252
2017 Q4	–	Sell	-4,000	Closed	-$202K	–	280
2017 Q3	$202K	Hold	4,000	–	–	0.05%	198
2017 Q2	$218K	Buy	+4,000	New	+$191K	0.06%	191

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's IART Position: Q2 2023 in Review

Stanley-Laman Group sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 4,000 shares — an estimated $230K sold.

Stanley-Laman Group first reported a position in IART in Q2 2017 and held it in 18 quarters. The position peaked at $276K in Q1 2021. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

Stanley-Laman Group reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
Stanley-Laman Group sold 4,000 Integra LifeSciences shares in Q2 2023, an estimated $230K.
Stanley-Laman Group first reported a position in Integra LifeSciences in Q2 2017 and held it in 18 quarters.
Stanley-Laman Group's Integra LifeSciences position peaked at $276K in Q1 2021.
283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on Stanley-Laman Group's 13F filing for Q2 2023, filed 8 Aug 2023.